NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

Patients not dying is always a good thing.

But the terrible irony that this delays making the treatment available for the many other patients who could not get in the trial.

That's why HE and EAMS could have been so great.

It would have enabled early access, while getting the word out there.

Instead its as if we were just business as usual with HE and EAMS being nothing more than a feel good validation that we're on to something and the regulators seem to see it to.